Prostaglandin-induced cortical hyperostosis. Case report and review of the literature.

Gardiner, J S; Zauk, Adel; Donchey, S S; McInerney, Vincent K.

doi:10.2106/00004623-199506000-00014

Cited by 11 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, a small minority of bone dysplasias have been associated with specific environmental exposures, in utero as well as after birth. Examples include some forms of chondrodysplasia punctata due to maternal autoimmune disorders, prenatal vitamin K deficiency, or use of certain medications, such as warfarin (Irving, Chitty, Mansour, & Hall, 2008) and cortical hyperostosis, following post-natal administration of prostaglandin E1 in the management of congenital heart disease (Gardiner, Zauk, Donchey, & McInerney, 1995).…”

Section: Introductionmentioning

confidence: 99%

Chondrodysplasia and growth failure in children after early hematopoietic stem cell transplantation for non‐oncologic disorders

Botto

Meeths

Campos‐Xavier

et al. 2021

American J of Med Genetics Pt A

View full text Add to dashboard Cite

Bone dysplasias (osteochondrodysplasias) are a large group of conditions associated with short stature, skeletal disproportion, and radiographic abnormalities of skeletal elements. Nearly all are genetic in origin. We report a series of seven children with similar findings of chondrodysplasia and growth failure following early hematopoietic stem cell transplantation (HSCT) for pediatric non-oncologic disease: hemophagocytic lymphohistiocytosis or HLH (five children, three with biallelic HLH-associated

show abstract

Section: Introductionmentioning

confidence: 99%

Chondrodysplasia and growth failure in children after early hematopoietic stem cell transplantation for non‐oncologic disorders

Botto

Meeths

Campos‐Xavier

et al. 2021

American J of Med Genetics Pt A

View full text Add to dashboard Cite

show abstract

“…Multiple case reports describe neonates who developed periostitis following prolonged PGE1 treatment. In these cases, the periostitis has regressed gradually following discontinuation of PGE1 [ 14 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study

Ofek Shlomai,

Lazarovitz,

Koplewitz

et al. 2023

Children

View full text Add to dashboard Cite

Objective: This study aimed to assess the association between treatment characteristics of prostaglandin E1 including initiation time and duration, maximal and cumulative doses, and adverse effects. Design: A retrospective cohort study in which medical records of neonates with duct-dependent lesions were studied for treatment parameters and adverse effects. Multivariable logistic regression model was applied for testing the effect PGE1 variables on outcomes. Main outcome measures: The primary outcomes of this study were association of adverse effects of PGE1 treatment with maximal dose, cumulative dose, and treatment duration. The secondary outcomes included safety of feeding in infants treated with PGE1. Results: Eighty-two infants with duct-dependent lesions receiving PGE1 were included. Several infants who received early PGE1 treatment required ventilation support. Feeds were ceased more often as the cumulative dose and duration of PGE1 treatment increased. Gastrointestinal adverse effects were significantly associated with the cumulative dose of PGE1 and treatment duration. Apneas, hyperthermia, and tachycardia were associated with maximal dose. Our data did not demonstrate a difference in the incidence of NEC associated with characteristics of PGE1 treatment. Conclusion: Cumulative PGE1 dose is associated with gastrointestinal adverse effects in neonates. Lower doses should be considered in neonates expecting prolonged PGE1 treatment.

show abstract

“…Hyperostosis is a well‐known long‐term complication of prostaglandin infusion. There was no correlation between dose and the onset; however, the length of the treatment seems to increase the chance of developing this condition, reaching up to 100% if given for more than 60 days . The mechanism of prostaglandin‐induced hyperostosis is not known, but it is a self‐limiting condition .…”

mentioning

confidence: 98%

“…There was no correlation between dose and the onset; however, the length of the treatment seems to increase the chance of developing this condition, reaching up to 100% if given for more than 60 days . The mechanism of prostaglandin‐induced hyperostosis is not known, but it is a self‐limiting condition . Differential diagnoses include conditions which produce diffuse periosteal reaction such as osteogenesis imperfecta, nonaccidental injury, congenital syphilis, osteomyelitis, Wiskott–Aldrich syndrome and infantile cortical hyperostosis (Caffey's Disease) .…”

mentioning

confidence: 99%

Hyperostosis: an under‐recognized complication of prostaglandin infusion

Abdelaziz

John

2013

Acta Paediatrica

View full text Add to dashboard Cite

Prostaglandin-induced cortical hyperostosis. Case report and review of the literature.

Cited by 11 publications

References 28 publications

Chondrodysplasia and growth failure in children after early hematopoietic stem cell transplantation for non‐oncologic disorders

Chondrodysplasia and growth failure in children after early hematopoietic stem cell transplantation for non‐oncologic disorders

Cumulative Dose of Prostaglandin E1 Determines Gastrointestinal Adverse Effects in Term and Near-Term Neonates Awaiting Cardiac Surgery: A Retrospective Cohort Study

Hyperostosis: an under‐recognized complication of prostaglandin infusion

Contact Info

Product

Resources

About